|
|
|
|
NAME
Zalcitabine, ddc |
BRAND
Hivid |
CLASS
Nucleoside analog (also called nucleoside reverse transcriptase inhibitor, NRTI or nuke) |
COST
$2,808/yr., $234/month |
STANDARD DOSE
One 0.75mg tablet three times a day, no food restrictions. Liquid available through compassionate use program. Take missed dose as soon as possible, but do not double a dose. |
POTENTIAL SIDE EFFECTS
Headache, fever, skin eruptions, canker sores, general inflammation of the mouth, nausea, pancreatitis, malaise (general ill-feeling, as with the blahs, fatigue, or a flu) and peripheral neuropathy neuropathy (tingling, burning, numbness or pain in the hands or feet, including nerve damage that is reversible but can be painful and permanent and permanently debilitating if not treated in time.) rare but potentially fatal toxicity with all NRTIs: pancreatitis (signs include nausea, vomiting, and abdominal pain that often spreads to the chest and back) lactic acidosis (seen mostly in women, especially obese women; greater risk for people with underlying liver disease; signs include deep muscle fatigue, especially in legs, and difficulty breathing) and enlarged, fatty liver (called heptaomegaly with steatosis), check for tenderness below the ribs on the right side.) |
POTENTIAL DRUG INTERACTIONS
Because of increased risks associated with peripheral neuropathy, according to the U.S. Department of Health and Human Services (HHS) HIV guidelines, whenever possible Hivid should not be taken with antiviral nucleoside analogues, Fungizone (amphotericin B) Chloromycetin (chloramphenicol) dapsone, Antabuse (disulfiram) Foscavir (foscarnet) isoniazid (for treating tuberculosis) Dilantin (phentoin) and Benemid (probenecid) Antacids decrease Hivid levels by 25 %. Tagamet (cimetidine). The risk of pancreatic increases with higher doses, more advanced HIV, and alcohol use. If you these symptoms stop taking Hivid and seek medical attention immediately If symptoms go away after stopping Hivid, you can consider starting Hivid again at a smaller dose. |
|
|
|
|
|
|
 |
|
